Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Clinical trial NCT02065869 · TERMINATED

Trial details

NCT number: NCT02065869
Sponsor: Bellicum Pharmaceuticals
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia Leukemia, Acute Myeloid (AML), Child Lymphoma, Non-Hodgkin Myelodysplastic Syndrome Primary Immunodeficiency Anemia, Aplastic Osteopetrosis Hemoglobinopathies Cytopenia Fanconi Anemia Diamond Blackfan Anemia Thalassemia

Start date: 2014-04-01
Primary completion: 2020-06-01
Enrollment: 187

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.